moxifloxacin has been researched along with dalcetrapib in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (dalcetrapib) | Trials (dalcetrapib) | Recent Studies (post-2010) (dalcetrapib) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 166 | 38 | 103 |
| Protein | Taxonomy | moxifloxacin (IC50) | dalcetrapib (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 4.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abt, M; Derks, M; Meneses-Lorente, G; Mwangi, A | 1 |
1 trial(s) available for moxifloxacin and dalcetrapib
| Article | Year |
|---|---|
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Topics: Administration, Oral; Adult; Amides; Anticholesteremic Agents; Area Under Curve; Arrhythmias, Cardiac; Aza Compounds; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Confidence Intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Esters; Fluoroquinolones; Heart; Humans; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Quinolines; Sulfhydryl Compounds; Young Adult | 2010 |